KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome

Orphanet Journal of Rare Diseases

Koichi Tanigawa⁴  Nobuoki Kohno³  Ulrich Costabel¹  Josune Guzman²  Nobuyuki Hirohashi⁴  Noboru Hattori³  Francesco Bonella¹  Yasumasa Iwasaki⁴  Takuma Sadamori⁴  Kazunobu Une⁴  Tadatsugu Otani⁴  Tomoko Tamura⁴  Kohei Ota⁴  Shinichiro Ohshimo⁴  Yoshiko Kida⁴ 

[1] Department of Pneumology/Allergy, Ruhrlandklinik, University Hospital, Essen, Germany;General and Experimental Pathology, Ruhr-University, Bochum, Germany;Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan;Department of Emergency and Critical Care Medicine, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan

关键词: Diffuse alveolar damage;    Interstitial lung disease;    Biomarker;    Outcome;    Survival;    Prognosis;   

Others  :  864169
DOI  :  10.1186/1750-1172-7-99

 received in 2012-08-28, accepted in 2012-12-11,  发布年份 2012

【 摘 要 】

Background

Diffuse alveolar hemorrhage syndrome is a life threatening condition with diverse etiologies. Sensitive prognostic markers for diffuse alveolar hemorrhage have not been well investigated. Serum KL-6 is a biomarker for various interstitial lung disease associated with disease activity and prognosis. The purpose of the present study was to evaluate the clinical utility of serum KL-6 level as a prognostic marker for diffuse alveolar hemorrhage.

Methods

We retrospectively collected 41 consecutive patients clinically diagnosed as having diffuse alveolar hemorrhage who were admitted to the Intensive Care Unit of Hiroshima University Hospital between 2004 and 2011. Correlation between prognosis and age, sex, laboratory findings including serum KL-6, radiological findings, ventilatory modes or therapeutic regimens were evaluated.

Results

Baseline and peak serum KL-6 levels were significantly higher in non-survivors compared with survivors. An increase in KL-6 levels during the initial week was associated with a subsequent deterioration of the oxygenation index. Higher baseline KL-6 levels and higher peak KL-6 levels were strongly correlated with death. With a cut-off level of 700 U/mL for peak KL-6, the sensitivity, specificity and accuracy for non-survival were 75%, 85% and 78%, respectively. In the multivariate analysis, only the peak KL-6 level ≥700 U/ml was an independent poor prognostic factor for diffuse alveolar hemorrhage.

Conclusions

Peak serum KL-6 level ≥700 U/ml may become a clinically useful marker of poor prognosis for diffuse alveolar hemorrhage.

【 授权许可】

   
2012 Kida et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Collard HR, Schwarz MI: Diffuse alveolar hemorrhage. Clin Chest Med 2004, 25:583-592.
• [2]Schwarz MI, Mortenson RL, Colby TV, Waldron JA, Lynch DA, Hutt MP, Cherniack RM, King TE Jr: Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation. Am Rev Respir Dis 1993, 148:507-511.
• [3]Rabe C, Appenrodt B, Hoff C, Ewig S, Klehr HU, Sauerbruch T, Nickenig G, Tasci S: Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care. J Crit Care 2010, 25:230-235.
• [4]Stahel RA, Gilks WR, Lehmann HP, Schenker T: Third International Workshop on lung tumor and differentiation antigens: overview of the results of the central data analysis. Int J Cancer Suppl 1994, 8:6-26.
• [5]Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989, 96:68-73.
• [6]Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, Abe M, Nishimura K, Higaki J, Ikezoe J, Kohno N: Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003, 58:872-875.
• [7]Ohshimo S, Bonella F, Grammann N, Starke K, Cui A, Bauer PC, Teschler H, Kohno N, Guzman J, Costabel U: Serum KL-6 as a novel disease marker in adolescent and adult cystic fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26:47-53.
• [8]Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, Hirasawa Y, Hiwada K: Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158:1680-1684.
• [9]Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, Bando M, Sugiyama Y, Totani Y, Ishizaki T, Ichiyasu H, Suga M, Hamada H, Kohno N: Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006, 11:164-168.
• [10]Burkhardt O, Kohnlein T, Wrenger E, Lux A, Neumann KH, Welte T: Predicting outcome and survival in patients with Wegener’s granulomatosis treated on the intensive care unit. Scand J Rheumatol 2007, 36:119-124.
• [11]Khan SA, Subla MR, Behl D, Specks U, Afessa B: Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest 2007, 131:972-976.
• [12]De Lassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C: Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 1995, 151:157-163.
• [13]European Society of Pneumology Task Group: Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Respir J 1989, 2:561-585.
• [14]Holguin F, Ramadan B, Gal AA, Roman J: Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am J Med Sci 2008, 336:321-326.
• [15]Afessa B, Tefferi A, Litzow MR, Peters SG: Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002, 166:1364-1368.
• [16]Specks U: Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol 2001, 13:12-17.
• [17]Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, Yokoyama A, Hamada H, Fujioka S, Hiwada K: KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993, 148:637-642.
• [18]Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS: Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med 1997, 156:109-115.
• [19]Determann RM, Royakkers AA, Haitsma JJ, Zhang H, Slutsky AS, Ranieri VM, Schultz MJ: Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med 2010, 10:6. BioMed Central Full Text
• [20]Seko A, Ohkura T, Ideo H, Yamashita K: Novel O-linked glycans containing 6′sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMBS cells: possible carbohydrate epitopes of KL-6 (MUC1) monoclonal antibody. Glycobiology 2011, 22:181-195.
• [21]Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N: KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun 2005, 338:1845-1852.
• [22]Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K: KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol 1997, 17:501-507.